What are the core diagnostic features of autism spectrum disorder (ASD)?

Autism is a behavioral diagnosis made by an expert, typically a psychiatrist or psychologist, based on two core features from the DSM-5: pervasive social interaction challenges and the presence of restricted repetitive behaviors. Beyond these, individuals with autism often experience anxiety, sensory challenges, seizure disorders, and sleep disorders, highlighting the condition's high clinical heterogeneity.

Is there a correlation between parents in STEM fields and having autistic children?

Studies on the Autism Quotient (AQ) have shown that individuals in intense STEM fields (engineering, physics, math) tend to have a greater burden of autistic traits, even if they do not have an autism diagnosis themselves. This suggests a continuous distribution of autistic traits across the general population, with higher prevalence in certain professions.

What is the role of genetics in autism, and how does it relate to the spectrum?

Autism is highly heritable, with about 40-80% attributed to genetic factors, particularly common genetic variants that are additive. This 'polygenic condition' concept suggests that a lower 'dosing' of these variants might lead to higher-functioning individuals, while single-gene, high-penetrance disorders can result in severe intellectual disability and lower functioning, contributing to the broad 'spectrum' of autism.

What environmental factors are known to increase the risk of autism?

Several environmental factors have been associated with an increased risk for autism, including advanced parental age, severe prematurity, and maternal illness during pregnancy. However, identifying specific environmental risk factors that universally impact all individuals with autism is complex due to genetic heterogeneity and the difficulty of conducting experimental studies in developing children.

What are oxytocin and vasopressin, and how do they differ?

Oxytocin and vasopressin are small, nine-amino-acid-long peptides, differing by only two amino acids, and are evolutionarily conserved across species. Oxytocin is peripherally involved in uterine contractions and milk let-down, often considered a 'female hormone.' Vasopressin (also called Arginine vasopressin or anti-diuretic hormone) is involved in urinary output regulation and blood pressure. Both are critically involved in social behavior in the brain.

What is oxytocin's role in human social behavior and autism treatment trials?

Initially dubbed the 'love' or 'trust' hormone, oxytocin can diminish the amygdala's response to fearful stimuli in humans, promoting pro-social effects. Early studies showed single-dose intranasal oxytocin could improve social functioning in high-functioning autistic males. However, a large multi-site trial showed no overall benefit, partly due to challenges in accurately measuring baseline oxytocin levels and a lack of funding for further research into specific subgroups (e.g. those with low baseline oxytocin levels).

Is early autism screening crucial for intervention?

Yes, early examination and intervention are highly beneficial. Research suggests that behavioral therapies, and potentially even oxytocin, may be maximally effective at younger ages (e.g., 2-5 or 3-6) due to greater brain neuroplasticity. However, significant barriers exist, such as long clinic wait times for specialist diagnosis and lack of readily available, inexpensive screening tools that could prioritize at-risk children for early support.

How was vasopressin discovered as a potential biomarker for autism?

Dr. Parker's lab developed a non-human primate model using Rhesus macaques to study naturally occurring social impairments. Through biomarker discovery, they found that cerebral spinal fluid (CSF) levels of vasopressin (not blood levels) were 93% accurate in classifying monkeys as low-social or high-social. This was replicated in a second monkey cohort, indicating CSF vasopressin's strong correlation with social functioning.

Does low vasopressin in infants predict a later autism diagnosis?

Dr. Parker's research, using 'liquid gold' samples of neonatal infant CSF, found that infants who later received an autism diagnosis already had low CSF vasopressin levels months or years before behavioral symptoms manifested. This suggests that low vasopressin could be a biomarker indicating a different developmental trajectory from birth, supporting early intervention strategies.

What are the clinical trial results for vasopressin treatment in children with autism?

In a small, double-blind, randomized, placebo-controlled pilot trial, children (6-12 years old) with autism treated with intranasal vasopressin twice daily for four weeks showed significant increases in social abilities. These improvements were reported by parents, observed by clinicians, and evidenced in laboratory-based social performance tests, indicating a promising therapeutic effect for social cognition and potentially reducing anxiety and restrictive repetitive behaviors.

How does the gut microbiome influence oxytocin and vasopressin production?

Mouse studies suggest an intriguing connection: probiotics, by increasing gut microbiota diversity, can normalize social functioning and upregulate oxytocin and vasopressin gene expression in the hypothalamus. This effect is mediated by the vagus nerve (the 'wandering nerve') directly connecting the gut to hypothalamic nuclei, implying that gut health can causally influence brain neuropeptide production and social behavior.

What is the current scientific consensus on vaccines and autism?

The initial theory linking vaccines to autism, proposed by Andrew Wakefield, was based on fraudulent data, leading to the retraction of his paper and the revocation of his medical license. Extensive subsequent studies have found no correlation between vaccination and autism. The scientific and medical community largely agrees that vaccines do not cause autism, though parents' concerns about vaccine numbers and contents are noted.

Key Moments

The Causes & Treatments for Autism | Dr. Karen Parker

Andrew Huberman

Science & Technology8 min read177 min video

Dec 11, 2023|455,360 views|9,211|2,123

andrew huberman huberman lab podcast huberman podcast dr. andrew huberman neuroscience huberman lab andrew huberman podcast the huberman lab podcast science podcast karen parker

Save to Pod

Key Moments

On this page

TL;DR

Dr. Karen Parker discusses autism's increase, genetic and environmental causes, and novel vasopressin treatments.

Key Insights

Autism prevalence has increased dramatically, now affecting 1 in 36 US children, with a significant male bias (3-4 boys for every girl). Early diagnosis is improving, but wait times for specialist evaluations are long.

Autism is a behavioral diagnosis, highly heterogeneous, and often linked to genetic factors (40-80% heritable), with a significant portion associated with common polygenic variants.

Traditional animal models (mice) have limitations in modeling human social behaviors, leading to high preclinical drug failure rates (50%). Non-human primate models offer a more accurate representation for social cognition research.

Oxytocin and vasopressin are evolutionarily conserved neuropeptides involved in social behavior. While oxytocin has received more attention, vasopressin is proving critical for social bonding and potential autism treatment.

Dr. Parker's research identified lower cerebral spinal fluid (CSF) vasopressin levels as a strong biomarker for social deficits in both socially impaired monkeys and children with autism, even in infants prior to behavioral symptom manifestation.

Clinical trials on intranasal vasopressin in children with autism show promising results in improving social abilities on parent reports, clinician evaluations, and laboratory tests, suggesting a potential future therapy, particularly for those with baseline low vasopressin levels.

THE RISING INCIDENCE AND DIAGNOSIS OF AUTISM

The prevalence of autism spectrum disorder (ASD) has seen a dramatic increase, reaching 1 in 36 U.S. children, up from 1 in 44 just two years prior. This rise is partly due to improved diagnostic capabilities, with clinicians now reliably identifying ASD in children as young as two to three years old, compared to nine or ten years in the past. Increased awareness, pediatrician-administered autism screeners, and a better understanding of the spectrum contribute to earlier detection. Autism exhibits a significant male bias, with studies showing 3 to 4 boys affected for every one girl, although this ratio can vary by monitoring site.

THE CHALLENGES OF DIAGNOSIS AND HETEROGENEITY

Autism remains a behavioral diagnosis based on two core features from the DSM-5: pervasive social interaction challenges and restricted repetitive behaviors. However, ASD is a highly heterogeneous disorder, meaning each individual presents a unique collection of traits, often accompanied by co-occurring conditions like anxiety, sensory issues, seizure disorders, and sleep disturbances. The current diagnostic methods, relying on expert clinical opinion, are time-consuming and non-scalable, leading to extensive wait times—sometimes 12 to 18 months—especially in under-resourced areas. The lack of a biological definition complicates diagnosis and treatment, raising the question of whether autism is a single disorder or a collection of many.

GENETIC AND ENVIRONMENTAL INFLUENCES

Autism is highly heritable, with genetic factors accounting for 40-80% of cases, often involving an additive effect of many common genetic variants. Environmental factors also play a role, including advanced parental age, severe prematurity, and maternal illness during pregnancy. Historically, various environmental hypotheses, such as prenatal ultrasound exposure, parental professions in STEM fields, and even vaccines, have been explored. While the vaccine hypothesis was debunked due to data fraud, the interplay between an individual's unique genetic background and environmental exposures makes identifying specific risk factors challenging. Stratified trials based on genetic subgroups are crucial for understanding these complex gene-by-environment interactions.

THE LIMITATIONS OF TRADITIONAL ANIMAL MODELS

Much of early autism research, particularly in drug development, relied on mouse models. However, mice fundamentally lack the complex cognitive and social abilities, vision-centric sensory processing, and sleep consolidation patterns necessary to accurately model the nuanced features of human autism. This discrepancy between species has contributed to a staggering 50% failure rate in preclinical drug trials when treatments successful in animals fail in human studies. The need for more sophisticated and translationally relevant animal models, particularly non-human primates, has become evident to bridge the gap between basic science and effective human therapies.

OXYTOCIN: THE "LOVE HORMONE" AND ITS ROLE IN AUTISM

Oxytocin, often called the “love hormone,” is a small peptide involved in social bonding and reproduction across species. In humans, it has been shown to diminish amygdala responses to fearful stimuli, suggesting a pro-social effect. Early single-dose clinical studies with intranasal oxytocin in high-functioning autistic males showed some potential benefits in social cognition tasks. However, a large multi-site Phase III trial ultimately reported no significant benefit. Dr. Parker's own research found that individuals with lower baseline blood oxytocin levels showed greater benefit from a four-week oxytocin intervention, suggesting a potential for targeted replacement therapy in a specific subgroup. However, funding for further oxytocin research has largely ceased due to the negative outcomes of broader trials.

INTRODUCING VASOPRESSIN: A PROMISING NEUROPEPTIDE

Vasopressin, a peptide structurally similar to oxytocin, was historically known for its peripheral roles in urine and blood pressure regulation. However, its critical role in male social behavior, pair bonding, and paternal care was revealed in early studies on voles. Dr. Parker's work in rhesus macaques, an old-world monkey species with complex social behaviors, established a primate model for naturally occurring social impairments. By refining human social responsiveness scales, she identified monkeys with autistic-like traits, characterized by increased isolation, diminished social motivation, and reduced affiliative behaviors like grooming. This model provided a robust platform for biomarker discovery.

CSF VASOPRESSIN: A NOVEL BIOMARKER FOR AUTISM

Using her primate model, Dr. Parker's team discovered that cerebral spinal fluid (CSF) vasopressin levels were a powerful differentiator between low-social and high-social monkeys, with 93% classification accuracy. Importantly, this difference was observed in CSF, not in blood, highlighting the need to sample closer to the brain for accurate insights into neurological conditions. This finding was replicated in a second monkey cohort and further extended to human cohorts. In children with autism, lower CSF vasopressin levels were directly correlated with greater social symptom severity, suggesting it as a robust biological indicator for autism and its social challenges, even in infants before behavioral symptoms manifest.

VASOPRESSIN DEFICITS AND EARLY INTERVENTION

The discovery of consistently low CSF vasopressin in infants who later developed autism provides compelling evidence of a potential pre-existing deficiency. This finding is critical because early behavioral interventions are known to be most effective when initiated at a young age, leveraging the brain's heightened neuroplasticity. Dr. Parker hypothesizes that a vasopressin deficiency in infancy could put individuals on an altered developmental trajectory for social functioning. Early vasopressin replacement therapy, if proven safe and effective, could potentially normalize this trajectory and reduce the severity of autism's social core features, offering a new avenue for intervention during critical developmental windows.

EFFICACY AND SAFETY OF INTRANASAL VASOPRESSIN

Dr. Parker and her colleague, Dr. Antonio Hardan, conducted the first-in-class, double-blind, randomized, placebo-controlled trial of intranasal vasopressin in children with autism (ages 6-12). The four-week treatment demonstrated significant improvements in social abilities, as reported by parents and clinicians, and observed in laboratory-based social performance tests. Notably, some children also experienced diminished anxiety and restricted repetitive behaviors. The trial indicated that intranasal vasopressin is relatively safe, with no severe adverse effects. This positive pilot data has spurred a larger replication trial to assess its broad utility and confirm its efficacy, underscoring the potential of vasopressin as a therapeutic agent for autism's social deficits.

CONTRADICTORY PHARMACEUTICAL APPROACHES

In contrast to Dr. Parker's approach, a major pharmaceutical company, Roche, pursued a different strategy by developing a vasopressin v1a receptor antagonist called balovaptan. Their trials aimed to block the v1a receptor, which is heavily implicated in social behavior. However, their preclinical rationale was unclear, and animal studies largely supported vasopressin as pro-social. Roche's trials ultimately yielded negative results on their primary outcome measure, the social responsiveness scale, and were eventually halted. This outcome inadvertently supports the hypothesis that augmenting, rather than blocking, vasopressin signaling is the more effective therapeutic direction for improving social functioning in autism.

MICROBIOME-GUT-BRAIN AXIS AND VASOPRESSIN

Emerging research suggests a fascinating link between the gut microbiome and vasopressin/oxytocin levels. Mouse models with social impairments, often characterized by altered gut microbiomes, have shown normalized social functioning and increased hypothalamic oxytocin and vasopressin expression following probiotic administration. This effect is mediated by the vagus nerve, which directly projects from the gut to the hypothalamus where these neuropeptides are produced. Severing the vagus nerve blunts this rescue effect. This discovery opens new research avenues, exploring whether gut microbiome modulation or vagus nerve stimulation could indirectly increase vasopressin production in autistic individuals, potentially offering non-pharmacological interventions.

THE VACCINE AND AUTISM CONTROVERSY

The theory that vaccines cause autism, largely propagated by a fraudulent paper by Andrew Wakefield, has been extensively debunked. Wakefield's work was retracted, and he lost his medical license due to scientific misconduct and fabricated data. Numerous subsequent studies have consistently found no correlation between vaccines and autism. While this controversy instilled widespread fear and diverted significant research funding, it also led to changes in vaccine preservatives. The initial reluctance of many researchers to investigate immunology in autism due to this contentious history is now slowly giving way to new inquiries into potential immune system dysregulation in a subset of individuals with autism, driven by persistent parental reports.

FUTURE DIRECTIONS AND THE URGENCY OF RESEARCH

The ongoing vasopressin research holds immense promise for transforming autism treatment. Future steps include larger replication trials, comprehensive neuroimaging studies to elucidate the mechanism of action, and investigation into potential genetic and physiological subgroups that may benefit most from vasopressin therapy. Bridging gaps in diagnostic access, particularly for underserved communities, and identifying early predictive biomarkers are crucial. The philanthropic funding landscape remains vital for novel, hypothesis-driven research that mainstream agencies might deem too risky. This tenacious pursuit of biological understanding and effective treatments reflects a commitment to alleviating suffering and enabling individuals with autism to reach their full potential, a mission that demands continued scientific rigor and public support.

Mentioned in This Episode

●Products

●Software & Apps

●Companies

●Organizations

●Books

●Concepts

●People Referenced

Common Questions

Both factors contribute to the observed increase. Improved screening by pediatricians and earlier diagnosis (now often at age 2-3, compared to 9-10 in the past) have increased detection. However, the prevalence rates themselves have also risen, with the US now at 1 in 36 children having an autism diagnosis, up from 1 in 44 two years ago, indicating a genuine increase in incidence, not just diagnosis.

Topics

Gut-Brain Axis Neuroscience & the Brain Mental Health & Psychology Clinical Trials Autism Spectrum Disorder Medicine & Clinical Social Cognition Primate Models Biomarker Discovery Early Intervention

Mentioned in this video

People

Antonio Hardan

A child psychiatrist and colleague of Dr. Parker at Stanford, who collaborates on double-blind, randomized, placebo-controlled vasopressin treatment trials in children with autism.

Joe Garner

A statistician who collaborated with Dr. Parker to develop machine learning algorithms to classify monkeys as high or low social based on neurotransmitter systems, identifying CSF vasopressin as a key driver.

Karen Parker

Guest on the Huberman Lab podcast and director of the Social Neurosciences Research Program at Stanford University School of Medicine, focusing on biological basis of social functioning and autism.

Pasko Rakic

Former head of neurobiology at Yale who proposed the idea that increased prenatal ultrasound might correlate with more neuronal migration errors, potentially linked to autism incidence.

Lauren Clark

A medical student in Dr. Parker's lab who wrote a perspective piece exploring the potential link between low vasopressin in autism and physiological features like excessive thirst or urination.

Andrew Wakefield

A researcher who published a fraudulent paper claiming that preservatives in vaccines caused autism, leading to the paper's retraction and the loss of his medical license.

John Constantino

A colleague, formerly at Washington University in St. Louis and now at Emory, who had a collection of neonatal infant CSF samples, referred to as 'liquid gold,' which were used to study vasopressin levels prior to autism diagnosis.

Adam Guella

A colleague at the University of Sydney who published research suggesting oxytocin may be most effective in autistic children at younger ages (2-5 or 3-6).

Rob Malenka

A colleague mentioned for his work on MDMA effects and for discussing vasopressin's role in male social behavior with Prairie voles.

Jim Simons

Runs one of the most successful hedge funds in the world and decided to invest significant money into autism research through the Simons Foundation.

Andrew Huberman

Host of the Huberman Lab podcast and a professor of neurobiology and ophthalmology at Stanford School of Medicine.

Dustin Hoffman

The actor who studied at the Devereux School to prepare for his role in the movie Rain Man, observing severely autistic children.

Sue Swedo

A professor at the NIH who was collecting cerebral spinal fluid as part of a research study interested in immune parameters and PANDAS deficiency.

Concepts

Central Diabetes Insipidus

A disorder characterized by excessive thirst and urination, potentially linked to very low vasopressin production. Researchers are investigating if a subset of autistic children exhibit these symptoms.

Prader-Willi Syndrome

A genetic syndrome with a manipulated Magel2 gene in mouse models, leading to social impairment and reduced oxytocin in the hypothalamus.

Rhesus Macaques

An old-world monkey species used to develop a primate model of naturally occurring social impairments that resemble human autism, identified using a modified Social Responsiveness Scale.

Fragile X syndrome

A neurogenetic syndrome with high penetrance for autism, meaning many individuals with it also receive an autism diagnosis. Mouse models of Fragile X show social impairment and reduced oxytocin in the hypothalamus.

Marmosets

A species of old world monkey mentioned in the context of thalidomide testing, where they exhibited limb abnormalities, demonstrating the importance of primate models for drug safety.

Timothy Syndrome

A condition resulting from a mutation in an L-type calcium channel, associated with both cardiac issues and autism.

Montane Voles

A species of vole that is asocial and polygamous, used in contrast to Prairie voles to understand vasopressin's role in social behavior.

Neurodivergence

A term used to describe individuals with neurological differences, related to having traits that are 'a little bit different' for those who self-identify as autistic but are high-functioning.

DSM-5

The diagnostic and statistical manual used by experts (psychiatrists or psychologists) for behavioral diagnosis of autism, based on two core features: pervasive social interaction challenges and restricted repetitive behaviors.

Vagus Nerve

Also known as the wandering nerve, it has a direct projection from the gut to the hypothalamus, where oxytocin and vasopressin are made. Its activation by probiotics can increase neuropeptide gene expression and social behavior in mice.

Catnap2 Mouse Model

A mouse model where genetic modification leads to social impairment and reduced oxytocin levels. Oxytocin administration during development can restore oxytocin neuron number.

Prairie Voles

A species of vole known for monogamous pair-bonding and paternal care, used in studies to show that vasopressin can induce these social behaviors.

Software & Apps

Autism Quotient

A measure designed in England, similar to the Social Responsiveness Scale, used to measure autistic traits. Studies show individuals in intense STEM fields have a greater burden of autistic traits when measured by AQ.

Social Responsiveness Scale

A US-based instrument used to measure autistic traits across the general population and as a primary outcome measure in vasopressin treatment trials for autism.

Macaca Social Responsiveness Scale Revised

A modified version of the human Social Responsiveness Scale used to measure autistic-like traits in monkeys.

Books

Proceedings of the National Academy of Sciences

A high-profile journal where Pasko Rakic published papers on neuronal migration and ultrasound effects.

Organizations

Autism Speaks

A parent grassroots organization resulting from lobbying efforts for autism research funding, which Dr. Parker became involved with.

FDA

The regulatory body that approves drugs for treatment. Only two antipsychotic drugs are currently FDA-approved for autism, treating irritability, not core features.

California National Primate Research Center

A primate center where Dr. Parker and her team developed a primate model of naturally occurring social impairments using Rhesus macaques.

CDC

In the US, the CDC has 11 monitoring sites across the country that collect data on child development, used to generate autism prevalence rates.

Simons Foundation

A foundation developed by Jim Simons that issues requests for applications for autism research, providing significant funding to the field.

NIH

An organization that had a mandate to include both sexes in research studies and where Dr. Sue Swedo collected CSF samples for immune parameter studies.

Products

Aeropress

A coffee maker developed by Alan Adler, an engineer at Stanford, known for making superior tasting coffee and being compact and easy to use. It's even suitable for brewing coffee while traveling.

Aerobie Frisbee

A frisbee developed by Allan Adler, which at one point held the Guinness Book of World Records for the furthest thrown object.

Drugs & Medications

MPTP

A street drug, a synthetic heroin, that caused overnight parkinsonian-like motor deficits in humans and other primates due to dopamine cell damage, but did not have the same effects in mice.

GHB

A substance mentioned in the context of a 1990s subculture that allegedly combined it with vasopressin as 'sex drugs,' though the rationale remains unclear.

Thalidomide

A morning sickness medication that caused profound limb abnormalities in children, as toxicity testing was done only in mice and not in primates like marmosets.

Companies

Netflix

A show mentioned as an example of seeing complex social cognition in chimpanzees, highlighting similarities to human social behavior.

LMNT

An electrolyte drink with zero sugar and appropriate ratios of sodium, magnesium, and potassium, crucial for nerve cell function and improved mental/physical performance. It comes in various flavors, including chocolate and chocolate mint, which can be enjoyed warm.

Eight Sleep

Sponsor of the podcast that makes smart mattress covers with cooling, heating, and sleep tracking capacity. It's noted for improving sleep quality by regulating body temperature.

Media

Rain Man

A movie for which Dustin Hoffman studied at the Devereux School, depicting characters with autism.